Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy' rating and a price target of $100, implying a potential upside of nearly 172% from the current price. This optimism is driven by the company's lead candidate, Claseprubart, which is what they refer to as a “best-in-class complement inhibitor.” The research firm believes that Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is in a good position to enhance treatment standards in three autoimmune conditions undergoing clinical testing: generalized myasthenia gravis (gMG), chronic idiopathic demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN), with each of these representing a market of up to $2 billion. Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now? While highlighting the company's latest Phase 2 data in gMG, Clear Street noted the prospects surrounding CIDP and MMN, with data updates projected for the latter half of next year. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has already deliver
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.MarketBeat
- Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.MarketBeat
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial ResultsGlobeNewswire
DNTH
Earnings
- 11/5/25 - Miss
DNTH
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 11/25/25 - Form SCHEDULE
- DNTH's page on the SEC website